Drug Profile
Adalimumab biosimilar - LG Chem
Alternative Names: LBALLatest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator LG Life Sciences
- Developer LG Chem; Mochida Pharmaceutical
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Rheumatoid arthritis
Most Recent Events
- 25 Nov 2021 Mochida Pharmaceuticals enter into a distribution and marketing agreement with AYUMI Pharmaceutical for adalimumab biosimilar in Japan
- 25 Nov 2021 Launched for Rheumatoid arthritis in Japan (SC)
- 06 Apr 2021 No development reported - Phase-III for Rheumatoid arthritis (Treatment-experienced) in South Korea and Japan (SC)